Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry
British Journal of Dermatology2016Vol. 176(4), pp. 1001–1009
Citations Over TimeTop 10% of 2016 papers
Jeffrey Zweegers, J.M.M. Groenewoud, J. M. P. A. van den Reek, Marisol E. Otero, P.C.M. van de Kerkhof, R.J.B. Driessen, P.P.M. van Lümig, M.D. Njoo, Paul M. Ossenkoppele, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, M.P.M. Andriessen, A.L.A. Kuijpers, M.A.M. Berends, Wietske Kievit, E.M.G.J. de Jong
Abstract
Compared with etanercept, ustekinumab had the highest effectiveness during 5 years of treatment. Patients receiving adalimumab and ustekinumab more often reached PASI 75 than those on etanercept at 1 year of treatment. Dose escalation was more frequent in etanercept and adalimumab than in ustekinumab.
Related Papers
- → Comparative Efficacy of Biologics in Psoriasis(2012)62 cited
- → Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis(2019)39 cited
- → Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?(2012)21 cited
- → PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis(2017)15 cited
- → The use of biologics for severe psoriasis(2015)3 cited